Ulcerative ColitisSymptoms, Doctors, Treatments, Advances & More
Ulcerative Colitis Overview
Learn About Ulcerative Colitis
Stephen Hanauer is a Gastroenterologist practicing medicine in Chicago, Illinois. Dr. Hanauer is rated as an Elite provider by MediFind in the treatment of Ulcerative Colitis. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy. Dr. Hanauer is board certified in American Board Of Internal Medicine - Gastroenterology (Certified). Dr. Hanauer is currently accepting new patients.
UChicago Medicine Northbrook
David Rubin is a Gastroenterologist and a Hepatologist practicing medicine in Northbrook, Illinois. Dr. Rubin is rated as an Elite provider by MediFind in the treatment of Ulcerative Colitis. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Ileostomy, and Endoscopy. Dr. Rubin is board certified in Practicing Since1994 and Gastroenterology. Dr. Rubin is currently accepting new patients.
NYU Langone Inflammatory Bowel Disease Center
David Hudesman is a Gastroenterologist practicing medicine in New York, New York. Dr. Hudesman is rated as an Elite provider by MediFind in the treatment of Ulcerative Colitis. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Hemorrhagic Proctocolitis, Ulcerative Colitis, Crohn's Disease, Small Bowel Resection, and Ileostomy.
Summary: This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).
Summary: The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.


